Inicio › Mieloma múltiple › Misuri
Ensayos clínicos de Mieloma múltiple en Misuri
27 estudios sobre Mieloma múltiple buscan participantes en Misuri.
Ciudades en Misuri
Texto oficial del estudio (inglés)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Belton
- MIVA Medical, Independence
- Kansas City VA Medical Center, Kansas City
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06152575A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Washington University School of Medicine in St. Louis, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07393282A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Washington University School Of Medicine, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07589634A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Washington University School Of Medicine, St Louis
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05201781A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Washington University School Of Medicine, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT04634552A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Washington University/Siteman Cancer Center, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07284758Collection of Tissue Samples for Cancer Research
- Washington University - St. Louis, St Louis
ReclutandoEstudio observacional
2 Months · Todos los sexos · Actualizado el 27 oct 2026 · NCT00900198A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Washington University School of Medicine, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04973605A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, St Louis
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07735637A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07681596Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07200102Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07200089A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Washington University School of Medicine, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06980480An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
- Washington University School of Medicine, St Louis
Reclutando
Edades de 18 a 99 · Todos los sexos · Actualizado el 8 oct 2026 · NCT07226934Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Washington University School of Medicine, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06297226A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07073547A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bridgeton
- GSK Investigational Site, Springfield
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07227311Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- y 19 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Washington University School of Medicine, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT06483100Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- Washington University School of Medicine, St Louis
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT06340646Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 jul 2026 · NCT06185751Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- y 3 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- y 21 más
ReclutandoFase 3
Todas las edades · Todos los sexos · Actualizado el 10 jun 2026 · NCT05561387Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Washington University /ID# 266972, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 may 2026 · NCT06896916Post-Op Pain Control for Prophylactic Intramedullary Nailing.
- Saint Louis University, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT03823534Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 mar 2026 · NCT06623630De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.